Who
Roger Mills
Chief Medical Officer
Company insider
Files Form 4 as: Chief Medical Officer, Addex Therapeutics; EVP, Development and Cmo, ACADIA Pharmaceuticals.
In numbers
- Trades disclosed
- 26
- Buys
- 0
- Sells
- 3
- Bought
- $0
- Sold
- $2.1M
- Companies
- 2
- Companies where not an officer
- 0
- First trade
- 30 Jun 2006
- Last trade
- 2 Sep 2026
- Last filed
- 4 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 2 Sep 2026filed 4 Sep 2026 | ADXN Addex TherapeuticsBiotechnology | SEC FORM 4 Code D | —392,837 at $0.00 | filing |
| 2 Sep 2026filed 4 Sep 2026 | ADXN Addex TherapeuticsBiotechnology | SEC FORM 4 Code A | —392,837 at $0.00 | filing |
| 2 Sep 2026filed 4 Sep 2026 | ADXN Addex Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —50,000 at $0.00 | filing |
| 2 Sep 2026filed 4 Sep 2026 | ADXN Addex Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —50,000 at $0.00 | filing |
| 2 Sep 2026filed 4 Sep 2026 | ADXN Addex Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
| 2 Sep 2026filed 4 Sep 2026 | ADXN Addex Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
| 2 Sep 2026filed 4 Sep 2026 | ADXN Addex TherapeuticsBiotechnology | SEC FORM 4 Code D | —392,837 at $0.00 | filing |
| 2 Sep 2026filed 4 Sep 2026 | ADXN Addex TherapeuticsBiotechnology | SEC FORM 4 Code A | —392,837 at $0.00 | filing |
| 20 Mar 2015filed 24 Mar 2015 | ACAD ACADIA Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —180,000 at $0.00 | filing |
| 26 Nov 2014filed 26 Nov 2014 | ACAD ACADIA PharmaceuticalsPharmaceuticals | SEC FORM 4 Code M | —25,000 at $0.00 | filing |
| 26 Nov 2014filed 26 Nov 2014 | ACAD ACADIA PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $752K25,000 at $30.09 | filing |
| 26 Nov 2014filed 26 Nov 2014 | ACAD ACADIA Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —25,000 at $0.00 | filing |
| 7 Mar 2014filed 11 Mar 2014 | ACAD ACADIA Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —155,000 at $0.00 | filing |
| 20 Sep 2013filed 20 Sep 2013 | ACAD ACADIA Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —35,965 at $0.00 | filing |
| 20 Sep 2013filed 20 Sep 2013 | ACAD ACADIA PharmaceuticalsPharmaceuticals | SEC FORM 4 Code M | —35,965 at $0.00 | filing |
| 20 Sep 2013filed 20 Sep 2013 | ACAD ACADIA PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $899K35,965 at $25.01 | filing |
| 7 Jun 2013filed 11 Jun 2013 | ACAD ACADIA Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —175,000 at $0.00 | filing |
| 1 Apr 2013filed 3 Apr 2013 | ACAD ACADIA PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $451K58,584 at $7.69 | filing |
| 23 Mar 2012filed 26 Mar 2012 | ACAD ACADIA Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —175,000 at $0.00 | filing |
| 23 Mar 2012filed 26 Mar 2012 | ACAD ACADIA Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —175,000 at $0.00 | filing |
News
Head-To-Head Comparison: ACADIA Pharmaceuticals (NASDAQ:ACAD) versus C4 Therapeutics (NASDAQ:CCCC)ACAD · tickerreport.com · 19 Oct 2026Critical Review: ACADIA Pharmaceuticals (NASDAQ:ACAD) and C4 Therapeutics (NASDAQ:CCCC)ACAD · dailypolitical.com · 15 Oct 2026ACADIA Pharmaceuticals (NASDAQ:ACAD) Cut to "Neutral" at UBS GroupACAD · themarketsdaily.com · 13 Oct 2026
0 headlines in the last 90 days name Roger Mills; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.